Drug profile

The FDA adverse-event record for Canine Influenza Virus H3N2, Kv

34 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Influenza Virus H3N2, Kv. Species, reactions, and outcomes follow.

#1348 of 2,679
by report volume (all drugs)
34
adverse-event reports
5.9%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Canine Influenza Virus H3N2, Kv ranks #1344 of 2679 by total reports (34). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1344
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Canine Influenza Virus H3N2, Kv has 34 reports now versus 34 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Canine Influenza Virus H3N2, Kv changes

Signature read: death-coded share at 5.9% is the most distinctive stamp on Canine Influenza Virus H3N2, Kv's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
34
Total Reports
2
Deaths Reported
5.9%
Death-coded share of reports

Active Ingredients

Canine Influenza Virus H3N2, Kv

Administration Routes

Subcutaneous

Species Affected

Dog 34

Most Affected Breeds

Retriever - Golden 4
Shepherd Dog - German 2
Retriever - Labrador 2
Dachshund (unspecified) 2
Shepherd (unspecified) 2
Corgi (unspecified) 2
Shepherd Dog - Belgian Malinois 1
Bloodhound 1
Bulldog 1
Siberian Husky 1

Most Reported Reactions

Vomiting 14
Lethargy (see also Central nervous system depression in 'Neurological') 12
Diarrhoea 9
Anorexia 8
Fever 5
Other abnormal test result NOS 5
Leucocytosis NOS 4
Seizure NOS 3
Polydipsia 3
Tachypnoea 3
Emesis 3
Pale mucous membrane 3

Outcome Breakdown

Ongoing
20 (58.8%)
Recovered/Normal
11 (32.4%)
Euthanized
2 (5.9%)
Outcome Unknown
1 (2.9%)

Canine Influenza Virus H3N2, Kv: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Canine Influenza Virus H3N2, Kv (#1348 of 2,679 by report volume); death-coded 5.9%. PlainBreed drug row · death-coded share stamp 5.9% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →